Document:

EXHIBIT
10.1

    

    CONFIDENTIAL TREATMENT
REQUESTED

    

    [*]
Denotes information for which
confidential treatment has been requested.  Confidential portions
omitted have been filed separately with the Securities and Exchange
Commission.

    

    AMENDMENT
FOUR

    TO
VALUE ADDED RESELLER PROGRAM AGREEMENT NUMBER AHA47

    BY
AND BETWEEN AGILENT TECHNOLOGIES, INC. AND

     O.I.
CORPORATION

    

    The above
referenced Value Added Reseller's Agreement (“Agreement") dated June 1, 2008
between Agilent Technologies, Inc. ("Agilent”) and O.I. Corporation (“Reseller”)
is hereby amended as follows:

    

    
      	
               
      

            	
              1.

            	
              Exhibit
      E305 Version 10 LSCA Value Added Reseller Compensation Exhibit is hereby
      deleted and replaced with the attached Exhibit E305 Version 12, effective
      July 1, 2010.

            

    

    

    ALL
OTHER TERMS AND CONDITIONS OF THE ABOVE REFERENCED

    VALUE
ADDED RESELLER PROGRAM AGREEMENT REMAIN UNCHANGED

    AND
IN FULL FORCE AND EFFECT.

     

    
      
        
          
            
              
                	
                        AGREED
      TO:

                      	
                         

                      	 
      	AGREED
      TO:  
	 	 	 	 	 
	
                        Representative: 

                      	
                        O.I.
      Corporation

                      	 
      	
                        Agilent:

                      	
                        Agilent
      Technologies, Inc.

                      
	 	 	 	 	 
	 
      	
                        /s/ J. Bruce Lancaster

                      	 
      	 
      	
                        /s/ Miranda Pierce

                      
	 
      	 
      	 
      	 
      	 
      
	
                        Name:

                      	
                        J.
      Bruce Lancaster

                      	 
      	
                        Name
      :

                      	
                        Miranda
      Pierce

                      
	 
      	 
      	 
      	 
      	 
      
	
                        Title:

                      	
                        CEO/CFO

                      	 
      	
                        Title:

                      	
                        Contracts
      Specialist

                      
	 
      	 
      	 
      	 
      	 
      
	
                        Date:

                      	
                        6/29/2010

                      	 
      	
                        Date:

                      	
                        June
      30, 2010

                      
	 
      	 
      	 
      	 
      	 
      
	
                        Address:

                      	
                        151
      Graham Road

                      	 
      	
                        Address: 

                      	
                        2850
      Centerville Road

                      
	 
      	
                        College
      Station, TX 77845

                      	 
      	 
      	
                        Wilmington,
      DE
19808

                      

              

            

          

        

      

    

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    CONFIDENTIAL TREATMENT
REQUESTED

    
      	
              Agilent
      Technologies

            	
              AHA47

            
	 
      	
              Exhibit
      E305

            

    

    LSG/CAG
VALUE ADDED RESELLER COMPENSATION EXHIBIT 

    

    
      
        
          
            
              
                	
                        DISCOUNT SUMMARY TABLE

                      
	 
      	
                        COLUMN I

                      	 
      	
                        COLUMN II

                      	 
      	
                        COLUMN III

                      	 
      	
                        COLUMN IV

                      
	
                        Volume Discount (Section
      1)

                      	
                        [*]

                      	 
      	
                        [*]

                      	 
      	
                        [*]

                      	 
      	
                        [*]

                      
	
                        Volume Performance Discount
      (Section 2)

                      	
                        [*]

                      	 
      	
                        [*]

                      	 
      	
                        [*]

                      	 
      	
                        [*]

                      
	
                        TOTAL
      DISCOUNT PERCENTAGE

                      	
                        [*]

                      	 
      	
                        [*]

                      	 
      	
                        [*]

                      	 
      	
                        [*]

                      

              

            

          

        

      

    

    

    
      	
               
      

            	
              1.

            	
              VOLUME
      BASED DISCOUNT

            

    

    

    Eligible
Products, including applicable standard options, will receive discounts in
accordance with the following “Discount Percentage Schedule” at the Estimated
Volume level established under this Exhibit.  The discounts granted
under this Exhibit are in lieu of and not in addition to any other discounts
that might be available from Agilent with the exception of certain special
promotions that may be offered from time to time.

    

    
      
        
          
            	
                    DISCOUNT
      PERCENTAGE SCHEDULE

                  	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	
                    WORLDWIDE

                  	 
      	 
      	 
      	 
      
	
                    US
      DOLLAR NET

                  	
                    I

                  	
                    II

                  	
                    III

                  	
                    IV

                  
	 
      	 
      	 
      	 
      	 
      
	
                    100,000-499,999

                  	
                    [*]
      

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  
	
                    500,000-999,999

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  
	
                    1,000,000-1,999,999

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  
	
                    2,000,000-3,999,999

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  
	
                    4,000,000-6,499,999

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  
	
                    6,500,000-UP

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  	
                    [*]

                  

          

        

      

    

    

    PRODUCTS
SUBJECT TO DISCOUNT

    

    Reseller
is appointed for the following Products as defined by the solutions in the
Business Plan:

      

    
      
        
          	
                  COLUMN
      I

                	
                  ALL
      PRODUCTS FROM PRODUCT LINES

                	
                  AA

                  58

                  BC

                  JW

                	
                  Proprietary
      Supplies

                  Analytical
      Supplies

                  LC
      Columns

                  GC
      Columns

                
	 	 	 	 
	
                  COLUMN
      II

                	
                  SELECTED
      PRODUCTS FROM PRODUCT LINES

                	
                  AZ*
  

                  CA*
  

                  BZ*

                	
                  Gas
      Chromatography systems and related Products

                  Emerging
      Markets Measurement Solutions

                  Gas
      Chromatography/Mass Spectroscopy Systems and Related
    Products

                
	 	 	 	 
	
                  COLUMN
      III

                	
                  SELECTED
      PRODUCTS FROM PRODUCT LINES

                	
                  29*
  

                  MA

                  89*

                  LI

                	
                  Liquid
      Chromatography and related Products

                  Spectroscopy

                  LC
      Mass Spectrometers

                  Laboratory
      Informatics (excluding software services and support
    products)

                
	
                  COLUMN
      IV

                	
                  PRODUCTS
      FROM PRODUCT LINES

                	
                  8P

                	
                  Replacement
      Parts

                

        

      

    

    

    *Discounts
also include all ChemStations associated with these Products

    

    [*]  Denotes
information for which confidential treatment has been
requested.  Confidential portions omitted have been filed separately
with the Securities and Exchange Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    CONFIDENTIAL TREATMENT
REQUESTED

    
      	
              Agilent
      Technologies

            	
              AHA47

            
	 
      	
              Exhibit
      E305

            

    

    LSG/CAG
VALUE ADDED RESELLER COMPENSATION EXHIBIT 

    

    Notwithstanding
the foregoing, Agilent reserves the right to determine which Products are
eligible for discount.

    

    PL29
PRODUCTS NOT ELIGIBLE FOR DISCOUNT

    

    
      
        	
                G1411A

              	
                Oracle
      Client License

              
	
                G4240A

              	
                HPLC-Chip
      MS Interface for use with Agilent MS

              
	
                G1311C

              	
                1260
      Infinity Quaternary VL Pump

              
	
                G1312C

              	
                1260
      Infinity Binary VL Pump

              
	
                G4220B

              	
                1290
      Infinity Binary VL Pump

              
	
                G4288C

              	
                1220
      Infinity LC Gradient System VL

              
	
                G4290C

              	
                1220
      Infinity LC Gradient System
VL

              

      

    

    

    
      	
               
      

            	
              2.

            	
              VOLUME
      PERFORMANCE DISCOUNT

            

    

    

    Reseller
will receive a Volume Performance Discount of [*] percent ([*]%) on all orders
placed during the following six (6) month period for Products in Column II and
III, if Reseller’s total net purchases of Agilent Products under this Agreement
for the prior six (6) months equal or exceed one hundred percent (100%) of
volume target specified in Table 1 below.

    

    For new
Resellers the Volume Performance Discount will commence only after the initial
six (6) months of the Agreement period.  Reseller will not be eligible
to receive Volume Performance discount unless a business plan has been agreed to
between Reseller and Agilent.  Should this Agreement be renewed, this
section is also applicable during the first six (6) months of the renewal
period.

      

    TABLE
1

    NET
SALES VOLUME TARGET*

      

    
      
        
          	
                  1st Half – Agreement period

                	 
      	
                  2nd Half – Agreement period

                	 
      	
                  Agreement period – Annual Volume
      target

                
	
                  [*]

                	 
      	
                  [*]

                	 
      	
                  [*]

                

        

      

    

      

    *If Reseller’s initial agreement
period is less than 12 months the volume estimate will be prorated on the basis
of 12 months.

    

    
      	
               
      

            	
              3.

            	
              DEMO
      DISCOUNT

            

    

    

    Products
purchased for demonstration and development purposes receive an additional
discount of [*] percent ([*]%), subject to Section 7 in R200L.

    

    
      	
               
      

            	
              4.

            	
              WARRANTY

            

    

    

    The
following warranty terms shall apply:

    

    
      	
               
      

            	
              a)

            	
              Reseller
      will receive an on-site warranty for Products beginning upon Reseller’s
      acceptance and ending either ninety (90) days thereafter or on the date
      that Reseller ships the Product(s) to the end-user, whichever occurs
      first.  The end use warranty period for Products being ninety
      (90) days after Reseller’s acceptance or the date the Product is received
      by the end-user, whichever occurs
first.

            

    

    

    [*]  Denotes
information for which confidential treatment has been
requested.  Confidential portions omitted have been filed separately
with the Securities and Exchange Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    CONFIDENTIAL TREATMENT
REQUESTED

    
      	
              Agilent
      Technologies

            	
              AHA47

            
	 
      	
              Exhibit
      E305

            

    

    LSG/CAG
VALUE ADDED RESELLER COMPENSATION EXHIBIT 

    

    b)    Agilent
reserves the right to change the warranty.  Such changes will affect
only new orders.

    
      	
               
      

            	
              c)

            	
              Reseller
      may provide more extensive warranties to end-users for certain Products
      only to the extent it receives Agilent’s prior approval and provided
      further that Reseller indemnifies Agilent against damages, liability or
      claims arising from Reseller’s breach of such warranties or associated
      warranty service.

            

    

    d)    End-users
must provide proof of purchase to be eligible for Agilent warranty
service.

    

    WARRANTY
TO END USERS

    

    
      	
               
      

            	
              a)

            	
              Product
      warranty terms are provided with the Product, on quotations, upon request
      or at http://www.agilent.com/go/warranty_terms.  Each
      Product receives a global warranty which includes the standard warranty
      for the country of purchase.

            

    

    
      	
               
      

            	
              b)

            	
              Agilent
      warrants the Agilent hardware and consumables Products against defects in
      materials and workmanship and that the Product will conform to
      Specifications.  Agilent warrants that Agilent owned standard
      Software substantially conforms to
  Specifications.

            

    

    
      	
               
      

            	
              c)

            	
              If
      Agilent receives notice of defects or non-conformance during the warranty
      period, Agilent will, at its option, repair or replace the affected
      Product.  Reseller or end user will pay expenses for return of
      such Product(s).  Agilent will pay expenses for shipment of
      repaired or replacement Product(s).

            

    

    
      	
               
      

            	
              d)

            	
              THE
      ABOVE WARRANTIES ARE EXCLUSIVE, AND NO OTHER WARRANTY, WHETHER WRITTEN OR
      ORAL, IS EXPRESSED OR IMPLIED.  AGILENT SPECIFICALLY DISCLAIMS
      THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
      PURPOSE.

            

    

    

    [*]  Denotes
information for which confidential treatment has been
requested.  Confidential portions omitted have been filed separately
with the Securities and Exchange Commission.Unassociated Document

    Exhibit 10.1

     

    
      	
              AGREEMENT FOR
      RE-ENGINEERING AND MANUFACTURE OF NEW BDS
  DEVICE

            

    

    

    THIS
AGREEMENT is made and entered into as of the date last entered below and upon
the payment of $20,000 to GT for previous services provided, which payments must
be made to GT by no later than August 15, 2010 ("the Effective Date"), by and
between Guided Therapeutics, Inc. ("GT"), a corporation having an address of
5835 Peachtree Corners East, Suite D, Norcross, GA 30092 and Biofield Corp.
("BZEC"), a Delaware corporation, having an office at 175 Strafford Avenue,
Wayne, PA 19087.  In addition, prior to commencing work on the subject
project, GT shall receive a further payment from BZEC of $250,000 towards the
re-engineering and development of that certain BDS technology, which payment
must be made to GT no later than January 30, 2011.

    

    WHEREAS,
MARK FAUPEL, PhD ("DR. FAUPEL") owns the exclusive rights in and to technology
relating to electrical and ionic methods, apparatus, and devices for the in vivo
and in vitro screening and diagnosis of disease states, including the technology
described in more detail below,

    

    AND
WHEREAS, BZEC has entered into an agreement with DR. FAUPEL of even date
herewith, to obtain the exclusive rights to utilize the technology described
herein and eventual ownership of same,

    

    NOW
THEREFORE, for and in consideration of the foregoing and the mutual covenants
and agreements contained herein, the parties hereto agree as
follows:

    

    1. Definitions

    

    As used herein:

    

    1.1 "Licensed Technology" means any
technology pertaining to the utilization of electrical, electropotential, or
electrical impedance, for the noninvasive screening, detection, or diagnosis of
disease states in an organism, including but not limited to:

    

    (a) The patent application which
describes the invention of utilizing extremely low frequency electromagnetic
fields for the screening and diagnosis of disease states in an organism,
and

    

    1.2 "Licensed Method" means any method
which is claimed in a patent application.

    

    1.3 "Licensed Product(s)" means any
product, including devices and disposable components of the device system, which
are claimed in a patent application.

    

    1.4 "Agreement" means this Agreement
including all Exhibits attached to this Agreement together with any written
amendments of any of the foregoing.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    2.  License

    

    2.1  License.  Pursuant
to that certain Agreement between BZEC and
DR. FAUPEL, DR. FAUPEL has granted to BZEC the exclusive right and license to
use and exploit the Licensed Technology to make, have made, use, market, lease,
and sell Licensed Products and, if that agreement is fulfilled BZEC will own the
IP rights to the Licensed Technology.

    

    2.2  Developmental
Information.  Upon execution of this Agreement and the
Agreement with DR. FAUPEL, DR. FAUPEL shall provide GT with the Licensed
Technology and all information relating to the development of the Licensed
Technology, including but not limited to blueprints, working drawings, and data
and information relating to manufacture of Licensed Products.

    

    2.3  Ownership of
Technology.  Upon the payment by BZEC of all monies agreed to
be paid to DR. FAUPEL under the Agreement between DR. FAUPEL and BZEC, the
latter will then own the Licensed Technology and all information relating to the
development of the Licensed Technology, including but not limited to blueprints,
working drawings, and data and information relating to manufacture of Licensed
Products.  If the Agreement between DR. FAUPEL and BZEC fails, then
exclusive title to the Licensed Technology and all information relating to the
development of the Licensed Technology, including but not limited to blueprints,
working drawings, and data and information relating to manufacture of Licensed
Products shall remain with DR. FAUPEL.

    

    3.  Development and
Re-engineering

    

    3.1  GT agrees to use all
reasonable efforts to develop the new Biofield BDS Device ("Work"), as
follows:

    

    (a)  Plan.  The method
and approximate timing of the development and re-engineering of the new Biofield
Device is set forth in Exhibit "A," hereto;

    

    (b)  Cost.  Approximately
$400,000 to $500,0000 (see Exhibit "A");

    

    (c)  Timing.  Payment of
the initial $250,000 must be made to GT no later than January 30,
2011.  Completion of the re-engineering and development phase is
expected to occur within six (6) months of payment of the $250,000 to GT and
agreement by both BZEC and GT on product specifications, not including CE
inspection.

    

    (d)  Interim
Payments.  Within sixty (60) of the initial payment and GT's
commencement of Work, BZEC will pay $125,000 to GT.  Should GT not
receive this payment, GT reserves the right, at its sole discretion, to cease
further work until it receives the said payment or the Agreement terminates in
accordance with paragraph 7.1, below.

    

    (e)  Final
Payment.  Within thirty (30) days before the scheduled CE
inspection, BZEC will pay to GT the balance due.  Should GT not
receive this payment, GT reserves the right, at its sole discretion, to cease
further work until it receives the said payment or the Agreement terminates in
accordance with paragraph 7.1, below.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    4.  Manufacture of
Units

    

    4.1  Number of Units.  GT
shall manufacture a minimum of 100 Biofield Prototypes at cost (including parts,
labor, warranty and overhead) plus a profit margin of thirty-five (35%)
percent.

    

    4.2  Additional
work.  Any other work requested of GT by BZEC beyond the scope
of the development, re-engineering and manufacturing described in sections 3 and
4.1 above,  will

    be quoted
in advance and then accepted (by Purchase Order) or rejected by
BZEC.

    

    5.  Additional
Services.

    

    5.1  Any other services
requested by BZEC of GT shall be governed by a written request for a quote and
purchase order.

    

    6.  Confidentiality

    

    6.1  Agreement Terms.

    

    (a)  During the term or this
Agreement and for five (5) years thereafter, GT shall not divulge to any third
party any written information provided by BZEC and prominently marked
"CONFIDENTIAL" when so provided; provided, however, that GT shall not be
obligated to maintain as confidential any information now or hereafter in the
public domain through no fault of GT or any information ordered to be divulged
by a Court of competent jurisdiction, except that if BZEC shall default on this
Agreement, then this paragraph shall be of no effect.

    

    7.  Term and
Termination

    

    7.1  Duration.  This
Agreement shall commence upon the Effective Date.  This Agreement
shall terminate upon the completion by GT of the above-stated
tasks.  Should BZEC desire that GT manufacture additional Biofield
Devices, either a new contract may be entered by the parties hereto or the
parties hereto may amend this agreement.  If BZEC defaults in any
payment to GT required by this Agreement and remains in default for ten (10)
business days after notice of default from GT, GT may void this Agreement by
sending written Notice in accordance with paragraph 9.3.  If this
Agreement shall be terminated as immediately aforesaid, GT shall have no
obligation to perform any further work for BZEC or to return any monies paid to
it by BZEC under this Agreement.  GT will provide BZEC with copies of
blueprints, working drawings, and data and information relating to manufacture
of Licensed Products which it has created from the Effective Date to the default
date.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    8.  Cooperation.

    

    8.1  GT agrees to extend
reasonable efforts to answer inquiries from any funder of BZEC or its
representatives, counsel or consultants regarding the development,
re-engineering and/or manufacture of the Biofield Devices in accordance with
this Agreement.

    

    8.2  GT agrees to extend
reasonable efforts to answer inquiries from any major customer of BZEC or its
representatives, counsel or consultant regarding the development, re-engineering
and/or manufacture of the Biofield Devices in accordance with this
Agreement.

    

    9.  Miscellaneous and
General

    

    9.1  Interpretation.  The
parties are equally responsible for the preparation of this Agreement, and in
any legal proceeding the terms hereof shall not be more strictly construed
against one party than the other.

    

    9.2  Resolution of
Disputes.  In the event the parties have a dispute or claim of
any kind arising under this Agreement that they are unable to resolve through
direct communications, such dispute
shall be resolved through arbitration pursuant to the rules of the American
Arbitration Association; provided, however, that (1) the Federal Rules of
Evidence shall apply during any such arbitration, (2) any discovery permitted
during such arbitration shall be completed within ninety (90) days of
commencement of such arbitration, and (3) such arbitration shall be held in
Atlanta, GA if either party asserts a claim against the other.

    

    9.3 Notices.  All
notices, statements and reports required or contemplated herein by one party to
the other shall be in writing and shall be deemed to have been given upon
delivery in person or upon the expiration of seven (7) days after deposit in a
lawful mail depository, registered or certified mail postage prepaid, and
addressed as follows:

    

    If to BZEC:

    

    Biofield Corp.

    Suite One

    175 Strafford Avenue

    Wayne, PA 19087

    ATTN: Mark S. Pearlstein,
Esquire

    Facsimile: 610-687-7757

    E-mail: mspearls@att.net

    

    If to Guided Therapeutics,
Inc.:

    

    Guided Therapeutics, Inc.

    5835 Peachtree Corners East Suite
D

    Norcross, GA 30071

    ATTN: Mark I. Faupel,
Ph.D.

    Facsimile: 770-242-8639

    Email:
mfaupel@guidedinc.com

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    Either
party hereto may change the address to which notices to such party are to be
sent by giving notice to the other party at the address and in the manner
provided above.  Any notice herein required or permitted to be given
may be given, in addition to the manner set forth above, by telex, facsimile or
cable, provided
that the party giving such notice obtains acknowledge-ment by telex, facsimile
or cable that such notice has been received by the party to he
notified.  Notice made in this manner shall be deemed to have been
given when such acknowledgement has been transmitted.

    

    9.4  Assignments and
Inurement.  Except to the extent otherwise herein provided,
neither party shall grant, transfer, convey, sublicense or otherwise assign any
of its rights or delegate any of its obligations under this Agreement without
the prior written consent of the other, which consent shall not be unreasonably
withheld, except in connection with the reorganization or sale of substantially
all of the assets of the party's business or as otherwise explicitly permitted
in this Agreement, and any attempt to do so shall be of no
effect.  This Agreement shall be binding upon and inure to the benefit
of the successors and permitted assigns of the parties hereto.

    

    9.5  Prior
Inventory.  BZEC shall pay to GT the sum of $20,000, on or
before July 30, 2010, as full payment for any and all GT charges for storage of
existing BZEC materials stored at GT.  GT herein agrees that upon
receipt of this payment, for itself and for its affiliates, subsidiaries,
directors, officers, employees and any representative of any kind, it does
release and
forever discharge BZEC and its affiliates, subsidiaries, directors, officers,
employees and any representative of any kind from any
and all claims, demands, damages, costs, expenses, loss of services, actions and
causes of action, arising from the storage of the aforesaid BZEC materials at
GT.

    

    9.5 (a)  Prior Inventory --
Removal.

    

    BZEC shall be responsible to retrieve,
within sixty (60) days of the Effective Date of this Agreement, at its sole cost
and expense, all BZEC materials currently at GT, including but not limited to
old devices, schematics, brochures, etc.   If BZEC should fail to
retrieve the aforesaid materials within the specified time, ownership of these
materials shall, without more, revert to GT.

    

    9.6  Entire
agreement.  This Agreement constitutes the entire Agreement
between GT and BZEC with respect to the subject matter hereof and shall not be
modified, amended or terminated except as herein provided or except by another
agreement in writing executed by the parties hereto.

    

    9.7  Headings.  The
section and paragraph headings are for convenience and are not a part of this
Agreement.

    

    9.8  Severability.  All
rights and restrictions contained herein
may be exercised and shall be applicable and binding only to the
extent that they do not violate any applicable laws and are intended to be
limited to the extent necessary so that they will not
render this Agreement illegal, invalid or unenforceable. If any provision or
portion of any provision of this Agreement not
essential to the commercial purpose of this Agreement shall be held to be
illegal, invalid or unenforceable by a court of competent jurisdiction, it is
the intention of the parties that the remaining provisions or portions thereof
shall constitute their agreement with respect to the subject matter hereof, and
all such remaining provisions or portions thereof shall remain in full force and
effect. To the extent legally permissible, any illegal, invalid or unenforceable
provision of this Agreement shall be replaced by a valid provision which will
implement the commercial purpose of this illegal, invalid or unenforceable
provision.  In the event that any provision essential to the
commercial purpose of this Agreement is held to be illegal, invalid
or unenforceable and cannot be replaced by a valid provision which will
implement the commercial purpose of this
Agreement, this Agreement and rights granted herein shall
terminate.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    9.9  Choice of Law.  This
Agreement is acknowledged to have been made in and shall be construed in
accordance with the laws of the State of Georgia, United States of America;
provided that all questions concerning the construction or effect of Licensed
Patents shall be decided in accordance with the laws of the country
in  which the particular patent application concerned has been filed
or granted, as the case may be.

    

    9.10  Use of Names.  BZEC
shall not use GT's name, or the name of any entity affiliated with GT, in any
advertisement or sales material unless it obtains the prior written consent of
GT or the entity proposed to be named, which consent will not be unreasonably
withheld or delayed.  The only exception to the foregoing is that BZEC
may use the name of GT and any entity affiliated with GT (if required) for SEC
filings.

    

    IN WITNESS WHEREOF, GT has executed
this Agreement and BZEC has caused this Agreement to be executed by its duly
authorized representative as of the day and year written below.

    

      
        	 	GUIDED
      THERAPEUTICS, INC.	 
	 	 	 	 
	
                Date:
      July 27,
      2010  

              	
                By:
      

              	/s/ Mark
      L. Faupel  	 
	 	 	MARK
      L. FAUPEL, PH.D.,	 
	 	 	CEO
      and PRESIDENT	 
	 	 	 	 

      

    

     

    
      
        	 	BIOFIELD
      CORP.	 
	 	 	 	 
	
                Date:
      July 16,
      2010     

              	
                By:
      

              	/s/ David
      Bruce Hong	 
	 	 	David
      Bruce Hong	 
	 	 	President       	 
	 	 	 	 

      

    

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

     

     

    EXHIBIT
"A"

    

    

    See
Biofield GT Gant Chart -- sent in pdf.

     

     

    
      
         

      

      
        7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]